Azithromycin
| Code | Size | Price |
|---|
| TAR-T6401-50mg | 50mg | £115.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T6401-1mL | 1 mL * 10 mM (in DMSO) | £120.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T6401-100mg | 100mg | £138.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T6401-500mg | 500mg | £246.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Azithromycin is an antibiotic by inhibiting protein synthesis, used for the treatment of bacterial infections.
CAS:
83905-01-5
Formula:
C38H72N2O12
Molecular Weight:
748.98
Pathway:
Autophagy; ; Microbiology/Virology
Purity:
0.999
SMILES:
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
Target:
Antibacterial; Antibiotic; Autophagy
References
Fa N, et al. Biochim Biophys Acta, 2007, 1768(7), 1830-1838.
Fan Y, Li M, Ma K, et al. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway[J]. Cancer biology & therapy. 2019, 20(5): 617-632.
Cigana C, et al. P Biochem Biophys Res Commun, 2006, 350(4), 977-982.
Xu K K, Huang Y K, Liu X, et al. Organotypic Culture of Mouse Meibomian Gland: A Novel Model to Study Meibomian Gland Dysfunction In Vitro[J]. Investigative Ophthalmology & Visual Science. 2020, 61(4): 30-30.
Vandooren J, et al. Differential inhibition of activity, activation and gene expression of MMP-9 in THP-1 cells by azithromycin and minocycline versus bortezomib: A comparative study. PLoS One. 2017 Apr 3;12(4):e0174853.
Tyteca D, et al. Exp Cell Res, 2002, 281(1), 86-100.
Menzel M, et al. Azithromycin augments rhinovirus-induced IFN? via cytosolic MDA5 in experimental models of asthma exacerbation. Oncotarget. 2017 Mar 18.
Sugiyama K, et al. Clin Exp Immunol, 2007, 147(3), 540-546.
Xu K K, Huang Y K, Liu X, et al. Organotypic Culture of Mouse Meibomian Gland: A Novel Model to Study Meibomian Gland Dysfunction In Vitro. Investigative Ophthalmology & Visual Science. 2020, 61(4): 30-30
Fan Y, Li M, Ma K, et al. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway. Cancer biology & therapy. 2019, 20(5): 617-632.
Nicholson M W, Huang C Y, Wang J Y, et al. Cardio-and Neurotoxicity of Selected Anti-COVID-19 Drugs. Pharmaceuticals. 2022, 15(6): 765